Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Cancer Therapies02:49

Cancer Therapies

8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition.

Molecular therapy. Oncology·2026
Same author

Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus.

Molecular therapy. Advances·2026
Same author

Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.

Cell reports. Medicine·2024
Same author

Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification.

Molecular therapy. Oncology·2024

Related Experiment Video

Updated: May 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.2K

Oncolytic vaccines.

Noura B Elsedawy1, Stephen J Russell

  • 1Department of Molecular Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Expert Review of Vaccines
|October 16, 2013
PubMed
Summary
This summary is machine-generated.

Oncolytic viruses are powerful cancer vaccines that kill tumor cells directly and indirectly. Engineered to enhance immune responses, they show promise as future cancer immunotherapies.

More Related Videos

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
07:24

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

4.1K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Related Experiment Videos

Last Updated: May 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.2K
Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
07:24

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

4.1K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Oncolytic viruses (OVs) are engineered viruses that selectively infect and kill cancer cells.
  • OVs induce anti-tumor immune responses by releasing tumor antigens and danger signals, leading to direct and indirect tumor cell killing.
  • The balance between direct and indirect tumor cell killing is crucial for effective oncolytic virotherapy.

Purpose of the Study:

  • To review the mechanisms of oncolytic viruses in cancer vaccination.
  • To discuss the role of immunomodulatory genes in enhancing OV efficacy.
  • To highlight the potential of OVs as future cancer immunotherapies.

Main Methods:

  • Review of current literature on oncolytic virotherapy and cancer vaccines.
  • Analysis of clinical trial data for Talimogene laherparepvec.
  • Discussion of emerging OV strategies and their immunomodulatory properties.

Main Results:

  • Talimogene laherparepvec, an oncolytic herpes simplex virus, demonstrated improved response rates in a Phase III trial.
  • Oncolytic viruses can be engineered with immunomodulatory genes to enhance anti-tumor T cell responses.
  • OVs can overcome tumor microenvironment-mediated immunosuppression.

Conclusions:

  • Oncolytic viruses are versatile platforms for cancer vaccination, mediating both direct and indirect tumor cell killing.
  • Engineering OVs with immunomodulatory transgenes can significantly boost anti-tumor immunity.
  • Oncolytic virotherapy holds significant promise as a future immunotherapeutic strategy for cancer treatment.